TW200619227A - Mutant interleukin-15-containing compositions and suppression of an immune response - Google Patents

Mutant interleukin-15-containing compositions and suppression of an immune response

Info

Publication number
TW200619227A
TW200619227A TW094127391A TW94127391A TW200619227A TW 200619227 A TW200619227 A TW 200619227A TW 094127391 A TW094127391 A TW 094127391A TW 94127391 A TW94127391 A TW 94127391A TW 200619227 A TW200619227 A TW 200619227A
Authority
TW
Taiwan
Prior art keywords
suppression
immune response
containing compositions
mutant interleukin
heart
Prior art date
Application number
TW094127391A
Other languages
English (en)
Inventor
Xin-Xiao Zheng
Terry B Strom
Thomas Moll
Original Assignee
Hoffmann La Roche
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Beth Israel Hospital filed Critical Hoffmann La Roche
Publication of TW200619227A publication Critical patent/TW200619227A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW094127391A 2004-08-11 2005-08-11 Mutant interleukin-15-containing compositions and suppression of an immune response TW200619227A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60104204P 2004-08-11 2004-08-11
US60047804P 2004-08-11 2004-08-11

Publications (1)

Publication Number Publication Date
TW200619227A true TW200619227A (en) 2006-06-16

Family

ID=35839987

Family Applications (2)

Application Number Title Priority Date Filing Date
TW094127389A TW200613552A (en) 2004-08-11 2005-08-11 Mutant interleukin-15 polypeptides
TW094127391A TW200619227A (en) 2004-08-11 2005-08-11 Mutant interleukin-15-containing compositions and suppression of an immune response

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW094127389A TW200613552A (en) 2004-08-11 2005-08-11 Mutant interleukin-15 polypeptides

Country Status (4)

Country Link
US (2) US20060057102A1 (zh)
AR (2) AR050293A1 (zh)
TW (2) TW200613552A (zh)
WO (2) WO2006020849A2 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
AR050293A1 (es) * 2004-08-11 2006-10-11 Moll Tomas Polipeptidos de interleuquina-15 mutante
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
CA2636111C (en) 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
EP1921452A1 (en) * 2006-11-08 2008-05-14 Medizinische Hochschule Hannover Method for the diagnosis of leukemia
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20110020269A1 (en) * 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
NZ582330A (en) 2007-06-27 2012-05-25 Marinepolymer Tech Inc COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
AU2010253863B2 (en) * 2009-05-28 2016-01-28 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
US20150110825A1 (en) * 2013-09-24 2015-04-23 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
MX2017004838A (es) * 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
JP6800219B2 (ja) * 2015-09-16 2020-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
MX2019007357A (es) * 2016-12-21 2019-09-05 Cephalon Inc Anticuerpos que se unen especificamente a il-15 humana y usos de estos.
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3060410A1 (en) 2017-05-15 2018-11-22 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
EP3758729B1 (en) 2018-02-26 2024-11-06 Synthorx, Inc. Il-15 conjugates and uses thereof
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
MX2021014189A (es) 2019-05-20 2022-01-06 Cytune Pharma Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
US20230028399A1 (en) * 2020-01-13 2023-01-26 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
IL302321A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
MX2023004880A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.
MX2023015400A (es) 2021-06-23 2024-03-07 Cytune Pharma Variantes de interleucina 15.
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
CN113956346B (zh) * 2021-10-26 2024-03-01 西安龙腾景云生物科技有限公司 一种重组白介素-15变体
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
JP2001502521A (ja) * 1996-04-26 2001-02-27 ベス イスラエル デアコネス メディカル センター インターロイキン―１５の拮抗剤
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
AR050293A1 (es) * 2004-08-11 2006-10-11 Moll Tomas Polipeptidos de interleuquina-15 mutante
US20060104945A1 (en) * 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15

Also Published As

Publication number Publication date
US20060057102A1 (en) 2006-03-16
AR050693A1 (es) 2006-11-15
US20060057680A1 (en) 2006-03-16
WO2006017853A2 (en) 2006-02-16
WO2006020849A2 (en) 2006-02-23
TW200613552A (en) 2006-05-01
WO2006020849A3 (en) 2006-10-05
AR050293A1 (es) 2006-10-11
WO2006017853A3 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
TW200619227A (en) Mutant interleukin-15-containing compositions and suppression of an immune response
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
WO2009148915A3 (en) Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2007030810A3 (en) Multiparameter whole blood monitor and method
EA033415B1 (ru) Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
HUP0303332A2 (hu) Beültetett szerv vagy szövet ("graft") kilökődését szuppresszáló hatóanyagok
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MX2007005166A (es) Plantas de algodon tolerantes a la agresion.
AU2011338647A8 (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
NO20064964L (no) Behandling av svekket respiratorisk funksjon
HK1109783A1 (en) Use of cultured three-dimensional tissue for treating congestive heart failure
MX2009003239A (es) Alimentacion de ancianos a largo plazo.
NO20090205L (no) Cykliske derivater som modulatorer av kjemokin reseptor aktiviteten
UA86802C2 (ru) Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
IL168308A (en) Compositions containing roflumilast and formoterol
SI1610787T1 (sl) Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni
TW200420554A (en) A intra-airway administrating preparation
MXPA05010161A (es) Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
WO2007129093A3 (en) Hla peptide therapy
WO2004090095A3 (en) Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders
IL168307A (en) Compositions containing roflumilast and (r,r)-formoterol
MX2010004025A (es) Antagonistas de glucosaminoglicano basados en sdf-1 y metodos de uso de los mismos.